Pharmaceutical industry news and competitor announcements

Eli Lilly's Weekly Insulin Efsitora Effective in Type 2 Diabetes Trials

May 16, 2024, 12:29 PM

Eli Lilly announced on Thursday that its once-weekly insulin injection, efsitora, met the main goals in two late-stage trials evaluating its effectiveness in people with type 2 diabetes. The experimental insulin demonstrated blood sugar reduction consistent with commonly used daily basal insulin products. These results suggest that efsitora could offer a significant lifestyle improvement for patients by reducing the frequency of injections from daily to weekly.